MagicBullet Therapeutics
- Biotech or pharma, therapeutic R&D
The first targetable drug, Gleevec, is known as "MagicBullet"that can be selectively tartet and kill disease causing cells or pathogens without harming health cells.
Magicbullet Therapeutics is an early clinical stage biotechnology focusing on new therapeutic modality of TPD and next generation kinase inhibitors to develop first-in-class targeted anticancer drugs that can be regulate life-threatening disease with unmet needs..
Key driver of company asset, MBT-C101 (mtPI3K chaperon degrader) is first-in-class mtPI3K chaperon degrader for indications of breast cancer and colorectal cancers and the most advanced program (ACK1 dual inhibitor, MBT-K101) is preclinical stage for indications of colorectal cancers (CRC) and metastatic castration-resistance prostate cancer (mCRPC).
Address
Yeongdeungpo-guSouth Korea
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}